Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GLA | P06280 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HBB | P68871 | 2/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camptothecin SCHEMBL29360250 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL29351099 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL788063 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL28057307 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL29369924 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL4304557 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL6038 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL548833 | 0.99 | TOP1 (0.98) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL17112859 | 0.99 | TOP1 (0.98) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL3117386 | 0.99 | TOP1 (0.98) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050118600-A1 | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | US | claimed |
| EP-1492523-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-05 | — | — | EP | claimed |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | claimed |
| WO-2003043631-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-30 | — | — | WO | claimed |
| EP-0550621-B1 | METHOD FOR MAKING CERTAIN PYRANO 3',4':6,7]INDOLIZINO 1,2-b]QUINOLINONES | SMITHKLINE BEECHAM CORP (US) | 1998-11-11 | — | — | EP | claimed |
| US-5155225-A | Method for making certain pyrano[3',4':6,7]indolizino-[1,2-B]quinolinones | SMITHKLINE BEECHAM CORPORATION (US) | 1992-10-13 | — | — | US | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118370809-A | Protein antigens and uses thereof | 百欧恩泰美国公司 | 2024-07-23 | — | — | CN | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023227660-A1 | NECTIN-4 BINDING AGENTS | INNATE PHARMA (FR) | 2023-11-30 | — | — | WO | disclosed |
| WO-2003043631-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-30 | — | — | WO | disclosed |
| US-RE37410-E1 | THE CHEMOTHERAPEUTIC AGENT IS INCORPORATED INTO AN RELEASED FROM A SYNTHETIC POLYMERIC MATRIX BY DEGRADATION OF THE POLYMER MATRIX OR DIFFUSION OF THE AGENT OUT OF THE MATRIX OVER A PERIOD OF TIME OF AT LEAST EIGHT HOURS. | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-10-16 | — | — | US | disclosed |
| EP-0550621-B1 | METHOD FOR MAKING CERTAIN PYRANO 3',4':6,7]INDOLIZINO 1,2-b]QUINOLINONES | SMITHKLINE BEECHAM CORP (US) | 1998-11-11 | — | — | EP | disclosed |
| US-5651986-A | POLYMER MATRIX | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1997-07-29 | — | — | US | disclosed |
| US-5626862-A | DRUG DELIVERY FROM POLYMER MATRICES BY RELEASE FROM MATRIX BY DEGRADATION OF POLYMER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1997-05-06 | — | — | US | disclosed |
| US-5155225-A | Method for making certain pyrano[3',4':6,7]indolizino-[1,2-B]quinolinones | SMITHKLINE BEECHAM CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
| US-5155225-A | Method for making certain pyrano[3',4':6,7]indolizino-[1,2-B]quinolinones | SMITHKLINE BEECHAM CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | RNASE1, GUSB, DPEP1 | TOP1 304/4885ALDH1A1 291/4885MEN1 3082/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | TOP1 4279/4885ALDH1A1 3285/4885MEN1 3367/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | TOP1 4318/4885ALDH1A1 3081/4885MEN1 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.